Distinct molecular features of colorectal carcinoma with signet ring cell component and colorectal carcinoma with mucinous component
|
|
- Joseph Berry
- 6 years ago
- Views:
Transcription
1 & 2006 USCAP, Inc All rights reserved /06 $ Distinct molecular features of colorectal carcinoma with signet ring cell component and colorectal carcinoma with mucinous component Shuji Ogino 1,2,3, Mohan Brahmandam 2, Mami Cantor 2, Chungdak Namgyal 2, Takako Kawasaki 2, Gregory Kirkner 4, Jeffrey A Meyerhardt 2,3,4, Massimo Loda 1,2,3 and Charles S Fuchs 2,3,4 1 Department of Pathology, Brigham and Women s Hospital, Boston, MA, USA; 2 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; 3 Harvard Medical School, Boston, MA, USA and 4 Department of Medicine, Brigham and Women s Hospital, Boston, MA, USA Signet ring cell carcinoma and mucinous carcinoma are distinct subtypes of colorectal adenocarcinoma. The morphologic and molecular spectra of colorectal carcinomas with various signet ring cell components and colorectal carcinomas with various mucinous components, compared to non-mucinous adenocarcinomas, have not been examined. The study groups consisted of 39 carcinomas with various signet ring cell components ( the signet group ), 167 carcinomas with various mucinous components ( the mucinous group ), and 457 nonmucinous adenocarcinoma. We visually estimated the amounts of signet ring cell and mucinous components in tumors, and subclassified the signet and mucinous groups according to the amount of each component (r19, 20 49, and Z50%). We sequenced BRAF and KRAS, analyzed for microsatellite instability (MSI) and 18q loss of heterozygosity (LOH), and performed immunohistochemistry for TP53, cyclooxygenase-2 (COX2), MLH1, O-6-methylguanine DNA methyltransferase (MGMT), p16 (CDKN2A), and fatty acid synthase (FASN). Signet ring cell carcinoma (Z50% signet ring cell tumors) and r49% signet ring cell tumors showed similar molecular features. Except for MSI and MGMT, Z50% mucinous tumors and r49% mucinous tumors also showed similar molecular features. BRAF mutations, MSI, and MLH1 loss were more frequent in both the signet and mucinous groups than nonmucinous carcinoma. More frequent KRAS mutations and less frequent p16 loss and TP53 positivity were observed in the mucinous group than nonmucinous carcinoma. 18q LOH and COX2 overexpression were less common in the signet group than nonmucinous carcinoma. FASN levels were highest in the mucinous group, followed by nonmucinous carcinoma, and lowest in the signet group. In conclusion, a minor (r49%) signet ring cell or mucinous component in colorectal carcinoma suggests molecular features similar to Z50% signet ring cell or mucinous carcinoma, respectively. Signet ring cell carcinoma and mucinous carcinoma are related subtypes of colorectal adenocarcinoma, but have molecular features distinct from each other.. doi: /modpathol ; published online 12 August 2005 Keywords: BRAF; colon cancer; COX2; fatty acid synthase; MSI; mucinous; signet ring cell Signet ring cell colorectal carcinoma and mucinous colorectal carcinoma are subtypes of colorectal adenocarcinoma with prominent mucin secretion. A unique pathologic feature of signet ring cell carcinoma is the presence of signet ring cells, which Correspondence: Dr S Ogino, MD, PhD, Department of Pathology, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA. shuji_ogino@dfci.harvard.edu Received 3 June 2005; revised 8 July 2005; accepted 10 July 2005; published online 12 August 2005 are single tumor cells with intracytoplasmic mucin displacing their nuclei aside. In contrast, mucinous colorectal carcinoma is characterized by abundant extracellular mucin produced by tumor cells. By definition, a 50% or greater signet ring cell component is required for the designation of signet ring cell colorectal carcinoma. Mucinous colorectal carcinoma has also 50% or more mucinous components. Signet ring cell colorectal carcinoma has been associated with poor clinical outcomes. 1 6 A number of studies have examined the molecular features of signet ring cell colorectal carcinoma and mucinous
2 60 Signet ring cell/mucinous colorectal carcinoma colorectal carcinoma. 3 5,7 However, the molecular markers these studies examined were few. Furthermore, the biological significance of a minor signet ring cell or mucinous component (r49% of the tumor) in otherwise conventional colorectal adenocarcinoma has not been studied. In the current practice of surgical pathology, there is no definitive rule on how to report a minor component of signet ring cells or mucinous features in colorectal adenocarcinoma. We hypothesized that carcinomas with a r49% signet ring cell or mucinous component might have molecular features similar, if not identical, to colorectal carcinoma, with a Z50% signet ring cell or mucinous component, respectively. A number of genes and pathways have been implicated in colorectal carcinogenesis, and in some cases these genes show differential rates of alteration among different morphologic types of carcinoma. RAS and RAF proteins participate in the RAS RAF MEK ERK MAP kinase pathway, which mediates cellular responses to growth signals. 8 Somatic mutations of KRAS are common in various human cancers including colorectal carcinoma. Activating mutation of the BRAF gene is common in malignant melanoma, but less frequent in colorectal carcinoma. 9 BRAF mutations in colorectal carcinoma were reported to occur more commonly in those cases with high degree of microsatellite instability (MSI-H), 10 but less frequently in colorectal carcinoma in patients with germline mutation in one of mismatch repair genes than in sporadic MSI-H tumors. 11 Mutations of BRAF are associated with MLH1 promoter methylation in sporadic colorectal carcinoma, 12 and mucinous colorectal carcinoma. 4 Both signet ring cell colorectal carcinoma and mucinous colorectal carcinoma are associated with MSI-H. 3 5 In addition, frequent BRAF mutation and infrequent KRAS mutation have been reported in mucinous colorectal carcinoma, compared to nonmucinous adenocarcinoma. 4 Cyclooxygenase-2 (COX2) has been shown to be overexpressed in colorectal cancer, 13 and a high level of COX2 expression is associated with poor prognosis. 14 Recently, COX2 has been shown to be a target of mutant KRAS. 15 The new COX2-specific inhibitor celecoxib has been shown to inhibit the growth of colorectal cancer cells. 16 Fatty acid synthase (FASN) is involved in de novo lipogenesis, catalyzing the reaction steps in the conversion of acetyl-coa and malonyl-coa to longchain saturated fatty acid. 17 FASN overexpression is commonly observed in human cancers, including colorectal cancer FASN overexpression has been associated with poor prognosis in breast, ovarian, and prostate cancers, and soft tissue sarcomas. 18,20 22,26,27 FASN inhibitor C75 has antitumor activity, 28 and causes apoptosis of p53- deficient colon cancer cells. 29 The FASN inhibitor, Orlistat, used to treat obesity, may serve as a potential anticancer drug. 30 FASN overexpression may be beneficial for tumor cells to retain more energy source and survive. In this study, we characterize the molecular features of colorectal carcinoma with signet ring cell component, and colorectal carcinoma with mucinous component, but no signet ring cell component, and compared them to those of nonmucinous nonsignet ring cell colorectal adenocarcinoma. This study is the first to comprehensively examine the morphologic and molecular spectra of signet ring cell and mucinous differentiations in colorectal carcinoma. We analyzed for a number of molecular abnormalities, including BRAF, KRAS, MSI, 18q loss of heterozygosity (LOH), and expression of p53 (TP53), COX2, p16 (CDKN2A, also known as INK4a), O-6-methylguanine DNA methyltransferase (MGMT), MLH1, and FASN. Our results indicate that a minor signet ring cell or mucinous component in colorectal carcinoma implies molecular features similar to colorectal carcinoma, with a Z50% signet ring cell or mucinous component, respectively. Materials and methods Tissue Specimens and Histopathologic Evaluations Tissue collection and analysis in this study have been approved by the Dana-Farber/Harvard Cancer Center Institutional Review Board. Colorectal adenocarcinoma resection specimens were collected from participants of the Nurses Health Study and Health Professional Follow-up Study cohorts. 31,32 Informed consents from all study participants have been obtained prior to this study. Tumors were randomly selected from these cohorts, based on availability of tumor tissue samples and assay results at the time of this study. Hematoxylin and eosin-stained slides of the tumors were reviewed, and the percentages of signet ring cell component and mucinous component were estimated under a light microscope. Tumors with signet ring cells (consisting the signet group ) were classified according to the amount of their signet ring cell component: r19, 20 49, and Z50%. After excluding tumors with signet ring cells, tumors with any mucinous component (consisting the mucinous group ) were classified according to the amount of their mucinous components: r19, 20 49, and Z50%. The colorectal adenocarcinomas without any mucinous or signet ring cell component were designated as nonmucinous nonsignet ring cell adenocarcinoma (also referred to as nonmucinous carcinoma ). There were totals of 39 carcinomas with any signet ring cell component (the signet group), 167 carcinomas with any mucinous component (the mucinous group), and 457 nonmucinous carcinomas. Genomic DNA Extraction, and Sequencing of KRAS and BRAF For DNA extraction, tumor tissue on glass slides was manually dissected excluding pure normal tissue to
3 enrich tumor DNA. For tumors with a signet ring cell or mucinous component, we did not separate tumor DNA of the signet ring cell or mucinous areas from non-signet or nonmucinous areas. Instead, we analyzed pooled DNA from representative areas of the tumor. Normal DNA was obtained from normal colorectal tissue at resection margins. Genomic DNA was extracted using QIAmp DNA Mini Kit (Qiagen, Valencia, CA, USA). For whole genome amplification (WGA), genomic DNA was PCR-amplified using random 15-mer primers. 33 Procedures of WGA has been validated as previously described. 34 Methods of PCR and sequencing targeted for KRAS codons 12 and 13, and BRAF codon 600, have been previously described. 35 All forward sequencing results were confirmed by reverse sequencing. KRAS sequencing was validated by the pyrosequencing technology as described previously. 34 Analyses for MSI and 18q LOH The status of MSI was determined by analyzing variability in the length of the microsatellite markers from tumor DNA compared to normal DNA. In addition to the recommended MSI panel consisting of D2S123, D5S346, D17S250, BAT25, and BAT26, 36 we used BAT40, D18S55, D18S56, D18S67, and D18S487 (ie, 10-marker panel). Primers were as follows: BAT40-F, 5 0 -agc caa gat taa ctt cct aca cca caa c-3 0 ; BAT40-R, 5 0 -gta gag caa gac cac ctt gtc tc-3 0 ; D18S55-F, 5 0 -gtg tct tca ata ttg att ctc tat tct agc ct-3 0 ; D18S55-R, 5 0 -agc ttc tga gta atc tta tgc tgt g-3 0 ; D18S56-F, 5 0 -gtg tct tcc tga agg acc tgc ctg aga ta-3 0 ; D18S56-R, cta tac ttt tta ttg tta ggg tgt g-3 0 ; D18S67-F, 5 0 -ctt ggg ttc cat ctt cag gaa a-3 0 ; D18S67-R, 5 0 -gtg tct tat gag ata ggc cca aag cat c-3 0 ;D18S487-F,5 0 -gtg tct tgc caa att aaa aga atg tat att att gc-3 0 ; D18S487-R, 5 0 -gat ttt cct cgt gcg tgc tt-3 0. Either forward or reverse primer for each marker was labeled with fluorescence, and PCR products were electrophoresed and analyzed by ABI 3730 (Applied Biosystems, Foster City, CA, USA). PCR and DNA fragment analysis for all of the markers except for D2S123, D5S346, and D17S250 was performed in duplicate. High degree of MSI (MSI-H) was defined as having instability in 30% or more of the markers when results of seven or more markers were available. LOH at each locus (D18S55, D18S56, D18S67, or D18S487) was defined as 40% or greater reduction of one of two allele peaks in duplicated runs in tumor DNA when compared to normal DNA. A tumor was defined as 18q LOH positive when any informative marker showed LOH. A tumor was defined as 18q LOH negative when at least two markers were informative and no informative marker showed LOH. Immunohistochemistry for p53 (TP53), FASN, p16 (CDKN2A), MLH1, MGMT, and COX2 Methods of immunohistochemistry for TP53, p16, MLH1, and MGMT were described previously Signet ring cell/mucinous colorectal carcinoma We have described methods of COX2 immunohistochemistry. 35 For FASN immunohistochemistry, antigen retrieval was performed by incubating deparaffinized tissue sections in 10 mm citrate buffer (BioGenex, San Ramon, CA, USA) by a microwave for 15 min. Tissue sections were incubated with 3% H 2 O 2 (20 min) to block endogenous peroxidase, and then incubated with 10% normal goat serum in phosphate-buffered saline (10 min). Primary antibody against FASN (BD Biosciences, Mississauga, ON, Canada) (dilution 1:100) was applied for 60 min at room temperature. Then, Multilink secondary antibody (BioGenex) (20 min) and then streptavidin horseradish peroxidase (BioGenex) were applied (20 min). Sections were visualized by diaminobenzidine (DAB) (5 min) and methyl-green counterstain. FASN expression was interpreted as negative, weak (1 þ ), positive (2 þ ), and strongly positive (3 þ ), using normal colonic epithelial cells and adipose tissue as reference. Statistical Analysis Statistical analysis was performed using the SAS program (version 9.1, SAS Institute, Cary, NC, USA). w 2 test and Fisher s exact test (when a number of any category is less than 10) were utilized for the analysis on categorical data. In Tables 1 4, we ranked P-values as follows: between 0.05 and ( a ), between and 0.01 ( b ), between 0.01 and ( c ), between and ( d ), between and ( e ), and or less ( f ). Results MSI, MLH1 Loss, and 18q LOH MSI-H tumors were more frequent in the signet group (25% or above) and the mucinous group (16 38%) than in nonmucinous carcinoma (11%) (Table 1). There was a statistically significant difference in frequencies of MSI-H between Z50% mucinous tumors (38%) and r19% mucinous tumors (16%; Po0.01), and between 20 49% mucinous tumors (34%) and r19% mucinous tumors (16%; Po0.025). Consistent with the MSI results, MLH1 loss was more common in both the signet group (29 40%) and the mucinous group (13 30%) than in nonmucinous carcinoma (10%) (Table 1). 18q LOH was less common in r19% signet ring cell tumors (30%) than in nonmucinous carcinoma (64%) (Po0.005) (Table 1). BRAF and KRAS Mutations, and TP53 Immunohistochemistry The most common BRAF mutation is the p.val600glu mutation (V600E, previously called V599E mutation). All other mutations comprised only appro- 61
4 Signet ring cell/mucinous colorectal carcinoma 62 Table 1 MSI, MLH1 loss, and 18q LOH in colorectal carcinoma with signet ring cell and mucinous components and nonmucinous adenocarcinoma Type of colorectal carcinoma MSI-H (%) MLH1 loss (%) 18q LOH present (%) Carcinoma with signet ring cell component (the signet group) r19% 7/25 (28%) b1 7/25 (28%) b3 6/20 (30%) d % 2/3 (67%) a1 2/5 (40%) 1/2 (50%) r49% 9/28 (32%) d1 9/30 (30%) d4 7/22 (32%) b5 Z50% 2/8 (25%) 2/7 (29%) 4/7 (57%) Any 11/36 (31%) d2 11/37 (30%) d5 11/29 (38%) b6 Carcinoma with mucinous component (the mucinous group) r19% 11/70 (16%) b2,c 8/61 (13%) 30/54 (56%) 20 49% 15/44 (34%) b2,f1 11/37 (30%) e1 17/30 (57%) r49% 26/114 (23%) a2,d3 19/98 (19%) b4 47/84 (56%) Z50% 20/53 (38%) c,a2,f2 14/50 (28%) e2 20/38 (53%) Any 46/167 (28%) f3 33/148 (22%) e3 67/122 (55%) Nonmucinous adenocarcinoma 38/351 (11%) b1,a1,d1,d2,f1,d3,f2,f3 36/352 (10%) b3,d4,d5,e1,b4,e2,e3 194/304 (64%) d6,b5,b6 Superscripts for statistical significance: a1,a2 Po0.05; b1 b6 Po0.025; c1 Po0.01; d1 d6 Po0.005; e1 e3 Po0.001; f1 f3 Po LOH, loss of heterozygosity; MSI-H, microsatellite instability-high. Table 2 BRAF and KRAS mutations and TP53 immunohistochemistry in colorectal carcinoma with signet ring cell and mucinous components and nonmucinous adenocarcinoma Type of colorectal carcinoma BRAF mutants (%) KRAS mutants (%) TP53 positive (%) Carcinoma with signet ring cell component (the signet group) r19% 7/21 (33%) d1 9/27 (33%) 4/12 (33%) 20 49% 0/2 (0%) 1/3 (33%) 4/6 (67%) r49% 7/23 (30%) d2 10/30 (33%) 8/18 (44%) Z50% 2/9 (22%) 0/8 (0%) 3/4 (75%) Any 9/32 (28%) d3 10/38 (26%) 11/22 (50%) Carcinoma with mucinous component (the mucinous group) r19% 9/61 (15%) 32/66 (48%) e3 22/54 (41%) a % 10/41 (24%) d4 17/39 (44%) a1 11/27 (41%) r49% 19/102 (19%) b1 49/105 (47%) d5 33/81 (41%) b2 Z50% 14/51 (27%) e1 15/49 (31%) 13/42 (31%) d7 Any 33/153 (22%) e2 64/154 (42%) d6 46/123 (37%) d8 Nonmucinous adenocarcinoma 30/348 (8.6%) d1,d2,d3,d4,b1,e1,e2 102/376 (27%) e3,a1,d5,d6 181/322 (56%) a2,b2,d7,d8 Superscripts for statistical significance: a1,a2 Po0.05; b1,b2 Po0.025; d1 d8 Po0.005; e1 e3 Po Table 3 Loss of MGMT and p16 (CDKN2A), and COX2 expression in colorectal carcinoma with signet ring cell and mucinous components and nonmucinous adenocarcinoma Type of colorectal carcinoma MGMT loss (%) p16 loss (%) COX2 positive (%) Carcinoma with signet ring cell component (the signet group) r19% 5/19 (26%) 4/16 (25%) 9/14 (64%) 20 49% 0/2 (0%) 1/1 (100%) 0/2 (0%) r49% 5/21 (24%) 5/17 (29%) 9/16 (56%) Z50% 0/4 (0%) 1/4 (25%) 1/4 (25%) Any 5/25 (20%) 6/21 (29%) 10/20 (50%) c Carcinoma with mucinous component (the mucinous group) r19% 16/41 (39%) 6/45 (13%) a2,e1 35/44 (80%) 20 49% 10/19 (53%) b 4/19 (21%) 13/20 (65%) r49% 26/60 (43%) a1 10/64 (16%) a3,e2 48/64 (75%) Z50% 5/28 (18%) b,a1 11/31 (35%) a2,a3 23/35 (66%) Any 31/88 (35%) 21/95 (22%) e3 71/99 (72%) Nonmucinous adenocarcinoma 71/208 (34%) 101/240 (42%) e1,e2,e3 346/457 (76%) c Superscripts for statistical significance: a1 a3 Po0.05; b Po0.025; c Po0.01; e1 e3 Po0.001.
5 Signet ring cell/mucinous colorectal carcinoma Table 4 FASN expression in colorectal carcinoma with signet ring cell and mucinous components and nonmucinous adenocarcinoma 63 Type of colorectal carcinoma 3+ FASN (%) 2+ FASN (%) 1+ FASN (%) Negative Total cases analyzed Carcinoma with signet ring cell component (the signet group) r19% 1 (7.1%) 3 (21%) a2 5 (36%) 5 (36%) b % (100%) 2 r49% 1 (6.3%) 3 (18%) b1 5 (31%) 7 (44%) d 16 Z50% (100%) 0 1 Any 1 (5.9%) 3 (18%) c2 6 (35%) 7 (41%) c5 17 Carcinoma with mucinous component (the mucinous group) r19% 8 (19%) c1 25 (58%) a2,b2 7 (16%) a3 3 (7.0%) b4,b % 0 11 (58%) 5 (26%) 3 (16%) 19 r49% 8 (13%) 36 (58%) b1,c3 12 (19%) 6 (10%) d,b6 62 Z50% 4 (12%) 16 (50%) 6 (19%) 6 (19%) 32 Any 12 (13%) a1 52 (55%) c2,c4 18 (19%) b3 12 (13%) c5,a4 94 Nonmucinous adenocarcinoma 19 (5.9%) c1,a1 126 (39%) b2,c3,c4 101 (31%) a3,b3 75 (23%) b5,b6,a4 321 Superscripts for statistical significance: a1 a4 Po0.05; b1 b6 Po0.025; c1 c5 Po0.01; d Po ximately 4% of BRAF mutations in carcinomas. BRAF mutations were more frequent in the signet group (22 33%) and in the mucinous group (15 27%) than nonmucinous carcinoma (8.6%) (Table 2). KRAS mutation distributions (ie, prevalence of each codon 12 or codon 13 mutation among all KRAS mutations) in the signet group, the mucinous group, and nonmucinous carcinoma did not significantly differ (data not shown). The KRAS mutation frequency in r49% mucinous tumors (47%), but not that in Z50% mucinous tumors (31%), was significantly higher than nonmucinous carcinoma (27%) (Table 2). TP53 positivity was less frequently observed in the mucinous group (31 41%) than in nonmucinous carcinoma (56%) (Table 2). Expression of MGMT, p16 (CDKN2A), COX2, and FASN MGMT and p16 immunohistochemistry is shown in Figure 1. MGMT loss was less frequent in the signet group (0 26%) than in the 20 49% mucinous tumors (53%) and in nonmucinous carcinoma (34%), though statistical significance was not reached (Table 3). Interestingly, MGMT loss was more common in 20 49% mucinous tumors (53%) than in Z50% mucinous tumors (18%) (Po0.025). Loss of p16 was less common in r49% mucinous tumors (16%) than in nonmucinous tumors (42%; Po0.001) (Table 3). COX2 and FASN immunohistochemistry is shown in Figures 2 and 3, respectively. There was no significant difference in distributions of COX2 staining intensities among the mucinous group and nonmucinous carcinoma (B5% showing 3 þ expression, 30 50% 2 þ expression, 20 30% 1 þ expression) (data not shown). COX2 expression was less common in tumors with any signet ring cell component (50%) in nonmucinous carcinoma (76%; Po0.01) (Table 3). FASN expression was remarkable in that the mucinous group showed the highest levels of expression (58 77% with 3 þ or 2 þ positivity), followed by nonmucinous carcinoma (70% with 2 þ or 1 þ positivity), and the signet group most often showed low levels or no expression (B75% showing 1 þ or negative staining) (Table 4). Discussion Signet ring cell colorectal carcinoma and mucinous colorectal adenocarcinoma are pathologically related, specific subtypes of colorectal adenocarcinoma. By convention, at least 50% of signet ring cell or mucinous component is required for the designation of signet ring cell carcinoma or mucinous carcinoma, respectively. We hypothesized that tumors with even less than 50% signet ring cell or mucinous component in colorectal adenocarcinoma imply molecular features similar to carcinoma with 50% or more signet ring cell or mucinous component, respectively. Our results support this hypothesis. There were some molecular differences, specifically frequencies of MSI and MGMT loss, between Z50% mucinous carcinoma and r49% mucinous carcinoma. Statistically significant results by some of these pairwise comparisons might represent a result of multiple hypothesis testing, or a true biological difference. Nonetheless, in general, Z50% mucinous carcinoma and r49% mucinous carcinoma appear similar, if not exactly the same. With regard to Z50% signet ring cell carcinoma and r49% signet ring cell carcinoma, it seems that there is no significant difference. However, the number of tumors with a signet ring cell component, especially those with Z50% signet ring cell component, is small and more cases are necessary to draw definitive conclusions. In light of our observations, we recommend that pathologists try to identify and report any minor component of signet ring cell
6 Signet ring cell/mucinous colorectal carcinoma 64 Figure 1 MGMT and p16 (CDKN2A) immunohistochemistry in colorectal carcinoma. (a) MGMT expression in mucinous carcinoma. (b) Loss of MGMT expression in nonmucinous carcinoma. Note that positive staining in mesenchymal and inflammatory cells serves as internal positive controls. (c) p16 expression in nonmucinous carcinoma. Note that p16 staining is focal. (d) Loss of p16 expression in nonmucinous carcinoma. Note that positive staining in mesenchymal cells serves as internal positive controls (original magnifications all 400). or mucinous areas in colorectal carcinoma, with efforts to quantify the amount of such a component. Since targeted therapy against specific deranged oncoproteins or signal transduction pathways may be available in the future, any findings that imply distinct molecular features should be reported. We compared various molecular features between carcinoma with signet ring cell component (the signet group) and carcinoma with mucinous component, but no signet ring cell component (the mucinous group). There are molecular similarities among these groups, including higher frequencies of BRAF mutation, MSI, and MLH1 loss. However, there are a number of molecular differences between the signet and mucinous groups. The mucinous group showed more frequent KRAS mutations, higher levels of COX2, and FASN expression than the signet group. Our results suggest that the signet and mucinous groups have overlapping, but distinct, pathogenetic mechanisms from each other. Since chemotherapeutic agents that inhibit the activity of FASN have potential activity against many different cancers with FASN overexpression, 24,28 our results of FASN expression (the highest expression in the mucinous group, followed by nonmucinous carcinoma, and the lowest expression in the signet group) may have some implications in treatment for colorectal cancer by FASN inhibitors in the future. There are a number of differences between the signet group and nonmucinous non-signet ring cell carcinoma (simply referred to as nonmucinous carcinoma ). Compared to nonmucinous carcinoma, the signet group has more frequent BRAF mutations, MSI and MLH1 loss, less frequent 18q LOH, and lower COX2 level. There are also a number of differences between the mucinous group and nonmucinous carcinoma. Compared to nonmucinous carcinoma, the mucinous group has more frequent BRAF mutations, MSI, and MLH1 loss, less frequent TP53 mutation, and higher level of FASN expres-
7 Signet ring cell/mucinous colorectal carcinoma 65 Figure 2 COX2 immunohistochemistry in colorectal carcinoma. (a) No or little COX2 overexpression in colorectal carcinoma (top) relative to normal mucosa (bottom). (b) Weak (1 þ ) COX2 overexpression in carcinoma with mucinous component (bottom and right) relative to normal mucosa (top left). (c) Moderate (2 þ ) COX2 overexpression in colorectal carcinoma (left) relative to normal mucosa (right). (d) Strong (3 þ ) COX2 overexpression in colorectal carcinoma (left) relative to normal mucosa (right) (original magnifications all 200). sion. Both signet ring cell carcinoma and mucinous colorectal carcinoma have been associated with MSI. 3 5 KRAS mutations were less common in signet ring cell carcinoma (4/11 ¼ 36%) and mucinous carcinoma (11/29 ¼ 38%) than in nonmucinous carcinoma (18/30 ¼ 60%) in a Japanese study. 1 Other unique molecular abnormalities described in mucinous tumors include less frequent APC inactivation and KRAS mutation (28%). 4 Another study showed KRAS mutation frequency of 29% in mucinous tumors. 41 Our results of KRAS mutation in 33% of mucinous tumors are also consistent with these findings. Cyclooxygenase 2 (COX2) overexpression in colorectal carcinoma has been associated with poor prognosis. 14 Expression of phospholipase A2, a key enzyme for prostaglandin synthesis together with COX2, has been associated with TNF-alpha-induced apoptosis in colon cancer cells. 13 As lower COX2 levels have been reported in colorectal carcinoma with MSI, 42 we examined whether COX2 was expressed any differently among the signet group, the mucinous group, and nonmucinous carcinoma, depending on different MSI status. However, we did not observe any significant modifications of COX2 levels due to MSI status among these tumor groups (data not shown). Since COX2 is an attractive target of chemoprevention as well as targeted therapy for colorectal carcinoma, 16,43 further investigations on various aspects of COX2 in colorectal carcinogenesis are awaited. In conclusion, a minor signet ring cell or mucinous component in colorectal carcinoma implies molecular features similar to carcinoma with Z50% signet ring cell component (signet ring cell carcinoma) or carcinoma with Z50% mucinous component (mucinous carcinoma), respectively. Colorectal carcinoma with a signet ring cell component and carcinoma with a mucinous component are related subtypes of colorectal adenocarcinoma, but have distinct molecular features from each other.
8 Signet ring cell/mucinous colorectal carcinoma 66 Figure 3 FASN immunohistochemistry in colorectal carcinoma. (a) Little FASN expression in normal colonic mucosa. (b) Weak (1 þ ) FASN overexpression in colorectal carcinoma (right). Little FASN expression in normal mucosa (left). (c) Moderates (2 þ ) FASN overexpression in colorectal carcinoma. (d) Strong (3 þ ) FASN overexpression in colorectal carcinoma (original magnifications all 200). Acknowledgements This work was supported by NIH P01 CA and P01 CA We thank Graham Colditz, Walter Willett, Frank Speizer, Meir Stampfer, Edward Giovannucci, Eric Rimm, David Hunter, and all of the other staff members for establishment and follow-up of the two large epidemiologic cohorts, Nurses Health Study and Health Professional Follow-up Study. We thank Mari Mino-Kenudson and Jonathan Glickman for critical reading of the manuscript and helpful suggestions. Notes added in proofs Detailed immunohistochemical methods for MLH1, CDKN2A (p16), MGMT and COX2 were as follows: For MLH1 immunohistochemistry, antigen retrieval was performed by incubating deparaffinized tissue sections in 10 mm citrate buffer (BioGenex, San Ramon, CA, USA) in a pressure cooker by a microwave for 30 min. Tissue sections were incubated with 3% H 2 O 2 (20 min) to block endogenous peroxidase for 15 min, and then incubated with 10% normal goat serum in phosphate-buffered saline (10 min). Tissue sections were further incubated with avidin block (Vector Laboratories, Burlingame, CA, USA) for 20 min and then with biotin block (Vector Laboratories) for 20 min. Primary antibody against MLH1 (BD Pharmingen, San Jose, CA, USA) (dilution 1:100) was applied for 30 min at room temperature. Multilink secondary antibody (Bio- Genex) (20 min), and then streptavidin horse radish peroxidase (BioGenex) were applied (20 min). Sections were visualized by diaminobenzidine (DAB) (5 min) and methyl-green counterstain. Normal colonic epithelial cells and inflammatory cells served as internal positive controls. For CDKN2A (p16) immunohistochemistry, antigen retrieval was performed by incubating deparaffinized tissue sections in 10 mm citrate buffer (BioGenex) by a microwave for 30 min. Tissue
9 sections were incubated with 3% H 2 O 2 (20 min) to block endogenous peroxidase for 20 min, and then incubated with 10% horse serum (Vector Laboratories) in phosphate-buffered saline (20 min). Primary antibody Ab-7 clone against CDKN2A (LabVision, Fremont, CA, USA) (dilution 1:200) was applied overnight at 41C. Secondary antibody (Vector Laboratories) (30 min) and then avidin biotin complex conjugate (Vector Laboratories) were applied (30 min). Sections were visualized by DAB (5 min) and methyl-green counterstain. Some mesenchymal cells and inflammatory cells served as internal positive controls. For MGMT immunohistochemistry, antigen retrieval was performed by incubating deparaffinized tissue sections in 10 mm citrate buffer (BioGenex) by a microwave for 15 min. Tissue sections were incubated with 3% H 2 O 2 (20 min) to block endogenous peroxidase for 20 min, and then incubated with 10% horse serum (Vector Laboratories) in phosphate-buffered saline (20 min). Tissue sections were further incubated with avidin block (BioGenex) for 15 min and then with biotin block (BioGenex) for 15 min. Primary antibody against MGMT (Chemicon, Temecula, CA, USA) (dilution 1:50) was applied overnight at 41C. Secondary antibody (Vector Laboratories) (30 min) and then avidin biotin complex conjugate (Vector Laboratories) were applied (30 min). Sections were visualized by DAB (5 min) and methyl-green counterstain. Normal colonic epithelial cells and inflammatory cells served as internal positive controls. For COX2 immunohistochemistry, antigen retrieval was performed by incubating deparaffinized tissue sections in citrate buffer (BioGenex) by a microwave for 15 min, and letting the sections cool for at least 40 min. Tissue sections were incubated with 3% H 2 O 2 (20 min) to block endogenous peroxidase, and then incubated with Avidin Block (Vector Laboratories) (15 min), then with Biotin Block (Vector Laboratories) (15 min). Primary anti-cox2 antibody (Cayman Chemical, Ann Arbor, MI, USA) (dilution 1:300) was applied overnight at 41C. Then, secondary anti-mouse antibody (Vector Laboratories) was applied (20 min), avidin biotin complex conjugate (Vector Laboratories) was added and sections were visualized by DAB (5 min) and methyl-green counterstain. COX2 expression was interpreted as negative, weak (1 þ ), positive (2 þ ) and strongly positive (3 þ ), using normal epithelial and inflammatory cells as reference. References 1 Sasaki S, Masaki T, Umetani N, et al. Characteristics in primary signet-ring cell carcinoma of the colorectum, from clinicopathological observations. Jpn J Clin Oncol 1998;28: Tung SY, Wu CS, Chen PC. Primary signet ring cell carcinoma of colorectum: an age- and sex-matched Signet ring cell/mucinous colorectal carcinoma controlled study. Am J Gastroenterol 1996;91: Kawabata Y, Tomita N, Monden T, et al. Molecular characteristics of poorly differentiated adenocarcinoma and signet-ring-cell carcinoma of colorectum. Int J Cancer 1999;84: Song GA, Deng G, Bell I, et al. Mucinous carcinomas of the colorectum have distinct molecular genetic characteristics. Int J Oncol 2005;26: Kakar S, Smyrk TC. Signet ring cell carcinoma of the colorectum: correlations between microsatellite instability, clinicopathologic features and survival. Mod Pathol 2005;18: Wistuba II, Behrens C, Albores-Saavedra J, et al. Distinct K-ras mutation pattern characterizes signet ring cell colorectal carcinoma. Clin Cancer Res 2003;9: Alexander J, Watanabe T, Wu TT, et al. Histopathological identification of colon cancer with microsatellite instability. Am J Pathol 2001;158: Peyssonnaux C, Eychene A. The Raf/MEK/ERK pathway: new concepts of activation. Biol Cell 2001;93: Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417: Rajagopalan H, Bardelli A, Lengauer C, et al. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002;418: Wang L, Cunningham JM, Winters JL, et al. BRAF mutations in colon cancer are not likely attributable to defective DNA mismatch repair. Cancer Res 2003;63: Koinuma K, Shitoh K, Miyakura Y, et al. Mutations of BRAF are associated with extensive hmlh1 promoter methylation in sporadic colorectal carcinomas. Int J Cancer 2004;108: Dong M, Johnson M, Rezaie A, et al. Cytoplasmic phospholipase A2 levels correlate with apoptosis in human colon tumorigenesis. Clin Cancer Res 2005;11: Soumaoro LT, Uetake H, Higuchi T, et al. Cyclooxygenase-2 expression: a significant prognostic indicator for patients with colorectal cancer. Clin Cancer Res 2004;10: Smakman N, Kranenburg O, Vogten JM, et al. Cyclooxygenase-2 is a target of KRASD12, which facilitates the outgrowth of murine C26 colorectal liver metastases. Clin Cancer Res 2005;11: Kazanov D, Dvory-Sobol H, Pick M, et al. Celecoxib but not rofecoxib inhibits the growth of transformed cells in vitro. Clin Cancer Res 2004;10: Semenkovich CF. Regulation of fatty acid synthase (FAS). Prog Lipid Res 1997;36: Rossi S, Graner E, Febbo P, et al. Fatty acid synthase expression defines distinct molecular signatures in prostate cancer. Mol Cancer Res 2003;1: Swinnen JV, Heemers H, Deboel L, et al. Stimulation of tumor-associated fatty acid synthase expression by growth factor activation of the sterol regulatory element-binding protein pathway. Oncogene 2000;19: Alo PL, Visca P, Marci A, et al. Expression of fatty acid synthase (FAS) as a predictor of recurrence in stage I breast carcinoma patients. Cancer 1996;77: Gansler TS, Hardman III W, Hunt DA, et al. Increased expression of fatty acid synthase (OA-519) in ovarian 67
10 68 Signet ring cell/mucinous colorectal carcinoma neoplasms predicts shorter survival. Hum Pathol 1997; 28: Shurbaji MS, Kalbfleisch JH, Thurmond TS. Immunohistochemical detection of a fatty acid synthase (OA- 519) as a predictor of progression of prostate cancer. Hum Pathol 1996;27: Rashid A, Pizer ES, Moga M, et al. Elevated expression of fatty acid synthase and fatty acid synthetic activity in colorectal neoplasia. Am J Pathol 1997;150: Kuhajda FP. Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology. Nutrition 2000;16: Visca P, Alo PL, Del Nonno F, et al. Immunohistochemical expression of fatty acid synthase, apoptoticregulating genes, proliferating factors, and ras protein product in colorectal adenomas, carcinomas, and adjacent nonneoplastic mucosa. Clin Cancer Res 1999; 5: Takahiro T, Shinichi K, Toshimitsu S. Expression of fatty acid synthase as a prognostic indicator in soft tissue sarcomas. Clin Cancer Res 2003;9: Menendez JA, Vellon L, Colomer R, et al. Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity. Int J Cancer 2005;115: Kuhajda FP, Pizer ES, Li JN, et al. Synthesis and antitumor activity of an inhibitor of fatty acid synthase. Proc Natl Acad Sci USA 2000;97: Li JN, Gorospe M, Chrest FJ, et al. Pharmacological inhibition of fatty acid synthase activity produces both cytostatic and cytotoxic effects modulated by p53. Cancer Res 2001;61: Kridel SJ, Axelrod F, Rozenkrantz N, et al. Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity. Cancer Res 2004;64: Fuchs CS, Willett WC, Colditz GA, et al. The influence of folate and multivitamin use on the familial risk of colon cancer in women. Cancer Epidemiol Biomarkers Prev 2002;11: Colditz GA, Hankinson SE. The Nurses Health Study: lifestyle and health among women. Nat Rev Cancer 2005;5: Dietmaier W, Hartmann A, Wallinger S, et al. Multiple mutation analyses in single tumor cells with improved whole genome amplification. Am J Pathol 1999;154: Ogino S, Kawasaki T, Brahmandam M, et al. Sensitive sequencing method for KRAS mutation detection by pyrosequencing. J Mol Diagn 2005;7: Ogino S, Meyerhardt J, Cantor M, et al. Molecular alterations in tumors and response to combination chemotherapy with gefitinib (ZD1839, EGFR tyrosine kinase inhibitor) for advanced colorectal cancer. Clin Cancer Res 2005 (in press). 36 Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute Workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998;58: Reles A, Schmider A, Press MF, et al. Immunostaining of p53 protein in ovarian carcinoma: correlation with histopathological data and clinical outcome. J Cancer Res Clin Oncol 1996;122: Riethdorf L, Riethdorf S, Lee KR, et al. Human papillomaviruses, expression of p16, and early endocervical glandular neoplasia. Hum Pathol 2002;33: Esteller M, Hamilton SR, Burger PC, et al. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 1999;59: Kane MF, Loda M, Gaida GM, et al. Methylation of the hmlh1 promoter correlates with lack of expression of hmlh1 in sporadic colon tumors and mismatch repairdefective human tumor cell lines. Cancer Res 1997;57: Ikeda S, Shimizu Y, Fujimori M, et al. Immunohistochemical and mutational analyses of beta-catenin, Ki-ras, and p53 in two subtypes of colorectal mucinous carcinoma. Clin Cancer Res 2003;9: Karnes Jr WE, Shattuck-Brandt R, Burgart LJ, et al. Reduced COX-2 protein in colorectal cancer with defective mismatch repair. Cancer Res 1998;58: Dannenberg AJ, Lippman SM, Mann JR, et al. Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol 2005;23:
Supplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Sherman SI, Wirth LJ, Droz J-P, et al. Motesanib diphosphate
More informationa) Primary cultures derived from the pancreas of an 11-week-old Pdx1-Cre; K-MADM-p53
1 2 3 4 5 6 7 8 9 10 Supplementary Figure 1. Induction of p53 LOH by MADM. a) Primary cultures derived from the pancreas of an 11-week-old Pdx1-Cre; K-MADM-p53 mouse revealed increased p53 KO/KO (green,
More informationAbbreviations: P- paraffin-embedded section; C, cryosection; Bio-SA, biotin-streptavidin-conjugated fluorescein amplification.
Supplementary Table 1. Sequence of primers for real time PCR. Gene Forward primer Reverse primer S25 5 -GTG GTC CAC ACT ACT CTC TGA GTT TC-3 5 - GAC TTT CCG GCA TCC TTC TTC-3 Mafa cds 5 -CTT CAG CAA GGA
More informationSupplementary Table 3. 3 UTR primer sequences. Primer sequences used to amplify and clone the 3 UTR of each indicated gene are listed.
Supplemental Figure 1. DLKI-DIO3 mirna/mrna complementarity. Complementarity between the indicated DLK1-DIO3 cluster mirnas and the UTR of SOX2, SOX9, HIF1A, ZEB1, ZEB2, STAT3 and CDH1with mirsvr and PhastCons
More informationc Tuj1(-) apoptotic live 1 DIV 2 DIV 1 DIV 2 DIV Tuj1(+) Tuj1/GFP/DAPI Tuj1 DAPI GFP
Supplementary Figure 1 Establishment of the gain- and loss-of-function experiments and cell survival assays. a Relative expression of mature mir-484 30 20 10 0 **** **** NCP mir- 484P NCP mir- 484P b Relative
More informationSupplementary Document
Supplementary Document 1. Supplementary Table legends 2. Supplementary Figure legends 3. Supplementary Tables 4. Supplementary Figures 5. Supplementary References 1. Supplementary Table legends Suppl.
More informationSupplementary Materials
Supplementary Materials 1 Supplementary Table 1. List of primers used for quantitative PCR analysis. Gene name Gene symbol Accession IDs Sequence range Product Primer sequences size (bp) β-actin Actb gi
More informationSupplemental Data. Shin et al. Plant Cell. (2012) /tpc YFP N
MYC YFP N PIF5 YFP C N-TIC TIC Supplemental Data. Shin et al. Plant Cell. ()..5/tpc..95 Supplemental Figure. TIC interacts with MYC in the nucleus. Bimolecular fluorescence complementation assay using
More informationFigure S1. Analysis of genomic and cdna sequences of the targeted regions in WT-KI and
Figure S1. Analysis of genomic and sequences of the targeted regions in and indicated mutant KI cells, with WT and corresponding mutant sequences underlined. (A) cells; (B) K21E-KI cells; (C) D33A-KI cells;
More informationT ranscriptional inactivation by cytosine methylation at
1000 GASTROINTESTINAL CANCER CpG island methylator phenotype () of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies S Ogino, M Cantor, T Kawasaki,
More informationCD31 5'-AGA GAC GGT CTT GTC GCA GT-3' 5 ' -TAC TGG GCT TCG AGA GCA GT-3'
Table S1. The primer sets used for real-time RT-PCR analysis. Gene Forward Reverse VEGF PDGFB TGF-β MCP-1 5'-GTT GCA GCA TGA ATC TGA GG-3' 5'-GGA GAC TCT TCG AGG AGC ACT T-3' 5'-GAA TCA GGC ATC GAG AGA
More informationSupplementary Figure 1. ROS induces rapid Sod1 nuclear localization in a dosagedependent manner. WT yeast cells (SZy1051) were treated with 4NQO at
Supplementary Figure 1. ROS induces rapid Sod1 nuclear localization in a dosagedependent manner. WT yeast cells (SZy1051) were treated with 4NQO at different concentrations for 30 min and analyzed for
More informationNature Structural & Molecular Biology: doi: /nsmb Supplementary Figure 1
Supplementary Figure 1 U1 inhibition causes a shift of RNA-seq reads from exons to introns. (a) Evidence for the high purity of 4-shU-labeled RNAs used for RNA-seq. HeLa cells transfected with control
More informationClinical and Pathological Significance of Epigenomic Changes in Colorectal Cancer
Clinical and Pathological Significance of Epigenomic Changes in Colorectal Cancer Shuji Ogino, M.D., Ph.D. Associate Professor of Pathology Harvard Medical School Brigham and Women s Hospital Dana-Farber
More informationSupplementary Figure 1 a
Supplementary Figure a Normalized expression/tbp (A.U.).6... Trip-br transcripts Trans Trans Trans b..5. Trip-br Ctrl LPS Normalized expression/tbp (A.U.) c Trip-br transcripts. adipocytes.... Trans Trans
More informationSupplementary Table 2. Conserved regulatory elements in the promoters of CD36.
Supplementary Table 1. RT-qPCR primers for CD3, PPARg and CEBP. Assay Forward Primer Reverse Primer 1A CAT TTG TGG CCT TGT GCT CTT TGA TGA GTC ACA GAA AGA ATC AAT TC 1B AGG AAA TGA ACT GAT GAG TCA CAG
More informationCitation for published version (APA): Oosterveer, M. H. (2009). Control of metabolic flux by nutrient sensors Groningen: s.n.
University of Groningen Control of metabolic flux by nutrient sensors Oosterveer, Maaike IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it.
More informationToluidin-Staining of mast cells Ear tissue was fixed with Carnoy (60% ethanol, 30% chloroform, 10% acetic acid) overnight at 4 C, afterwards
Toluidin-Staining of mast cells Ear tissue was fixed with Carnoy (60% ethanol, 30% chloroform, 10% acetic acid) overnight at 4 C, afterwards incubated in 100 % ethanol overnight at 4 C and embedded in
More informationSupplementary Figures
Supplementary Figures Supplementary Figure 1. H3F3B expression in lung cancer. a. Comparison of H3F3B expression in relapsed and non-relapsed lung cancer patients. b. Prognosis of two groups of lung cancer
More informationEpigenetic profiling of synchronous colorectal neoplasias by quantitative DNA methylation analysis
& 2006 USCAP, Inc All rights reserved 0893-3952/06 $30.00 www.modernpathology.org Epigenetic profiling of synchronous colorectal neoplasias by quantitative DNA methylation analysis Shuji Ogino 1,2,3, Mohan
More informationSupplementary Figure 1 MicroRNA expression in human synovial fibroblasts from different locations. MicroRNA, which were identified by RNAseq as most
Supplementary Figure 1 MicroRNA expression in human synovial fibroblasts from different locations. MicroRNA, which were identified by RNAseq as most differentially expressed between human synovial fibroblasts
More informationTable S1. Oligonucleotides used for the in-house RT-PCR assays targeting the M, H7 or N9. Assay (s) Target Name Sequence (5 3 ) Comments
SUPPLEMENTAL INFORMATION 2 3 Table S. Oligonucleotides used for the in-house RT-PCR assays targeting the M, H7 or N9 genes. Assay (s) Target Name Sequence (5 3 ) Comments CDC M InfA Forward (NS), CDC M
More informationSUPPLEMENTARY INFORMATION
doi: 10.1038/nature05883 SUPPLEMENTARY INFORMATION Supplemental Figure 1 Prostaglandin agonists and antagonists alter runx1/cmyb expression. a-e, Embryos were exposed to (b) PGE2 and (c) PGI2 (20μM) and
More informationNature Immunology: doi: /ni.3836
Supplementary Figure 1 Recombinant LIGHT-VTP induces pericyte contractility and endothelial cell activation. (a) Western blot showing purification steps for full length murine LIGHT-VTP (CGKRK) protein:
More informationSUPPLEMENTARY DATA. Supplementary Table 1. Primer sequences for qrt-pcr
Supplementary Table 1. Primer sequences for qrt-pcr Gene PRDM16 UCP1 PGC1α Dio2 Elovl3 Cidea Cox8b PPARγ AP2 mttfam CyCs Nampt NRF1 16s-rRNA Hexokinase 2, intron 9 β-actin Primer Sequences 5'-CCA CCA GCG
More informationAstaxanthin prevents and reverses diet-induced insulin resistance and. steatohepatitis in mice: A comparison with vitamin E
Supplementary Information Astaxanthin prevents and reverses diet-induced insulin resistance and steatohepatitis in mice: A comparison with vitamin E Yinhua Ni, 1,2 Mayumi Nagashimada, 1 Fen Zhuge, 1 Lili
More informationCulture Density (OD600) 0.1. Culture Density (OD600) Culture Density (OD600) Culture Density (OD600) Culture Density (OD600)
A. B. C. D. E. PA JSRI JSRI 2 PA DSAM DSAM 2 DSAM 3 PA LNAP LNAP 2 LNAP 3 PAO Fcor Fcor 2 Fcor 3 PAO Wtho Wtho 2 Wtho 3 Wtho 4 DTSB Low Iron 2 4 6 8 2 4 6 8 2 22 DTSB Low Iron 2 4 6 8 2 4 6 8 2 22 DTSB
More informationSupplementary Materials and Methods
DD2 suppresses tumorigenicity of ovarian cancer cells by limiting cancer stem cell population Chunhua Han et al. Supplementary Materials and Methods Analysis of publicly available datasets: To analyze
More informationBIOLOGY 621 Identification of the Snorks
Name: Date: Block: BIOLOGY 621 Identification of the Snorks INTRODUCTION: In this simulation activity, you will examine the DNA sequence of a fictitious organism - the Snork. Snorks were discovered on
More informationSupplementary Figure 1a
Supplementary Figure 1a Hours: E-cadherin TGF-β On TGF-β Off 0 12 24 36 48 24 48 72 Vimentin βactin Fig. S1a. Treatment of AML12 cells with TGF-β induces EMT. Treatment of AML12 cells with TGF-β results
More informationMolecular Pathology of Ovarian Carcinoma with Morphological Correlation
Molecular athology of Ovarian Carcinoma with Morphological Correlation Kathleen R. Cho, M.D. Comprehensive Cancer Center and Departments of athology and Internal Medicine University of Michigan Medical
More informationPlasmids Western blot analysis and immunostaining Flow Cytometry Cell surface biotinylation RNA isolation and cdna synthesis
Plasmids psuper-retro-s100a10 shrna1 was constructed by cloning the dsdna oligo 5 -GAT CCC CGT GGG CTT CCA GAG CTT CTT TCA AGA GAA GAA GCT CTG GAA GCC CAC TTT TTA-3 and 5 -AGC TTA AAA AGT GGG CTT CCA GAG
More informationSupplementary Figure 1
Supplementary Figure 1 3 3 3 1 1 Bregma -1.6mm 3 : Bregma Ref) Http://www.mbl.org/atlas165/atlas165_start.html Bregma -.18mm Supplementary Figure 1 Schematic representation of the utilized brain slice
More informationMalignant Amelanotic Melanoma of the Pleura without Primary Skin Lesion: An Autopsy Case Report. a a*
2009 63 6 379 384 Malignant Amelanotic Melanoma of the Pleura without Primary Skin Lesion: An Autopsy Case Report a b a a a* a b 380 63 6 Chest x ray and computed tomography (CT). A, Chest x ray on admission
More informationCpG Island Methylator Phenotype-Low (CIMP-Low) in Colorectal Cancer: Possible Associations with Male Sex and KRAS Mutations
Journal of Molecular Diagnostics, Vol. 8, No. 5, November 2006 Copyright American Society for Investigative Pathology and the Association for Molecular Pathology DOI: 10.2353/jmoldx.2006.060082 CpG Island
More informationAssessment performed on Tuesday, July 29, 2014, at Lions Gate Hospital, North Vancouver
Assessors report for ciqc Run 37: BRAF V600E (April 2014) Assessors: B Gilks, R Wolber, K Ung, P Tavassoli, J Garratt and J Won (recorder) Assessment performed on Tuesday, July 29, 2014, at Lions Gate
More informationA smart acid nanosystem for ultrasensitive. live cell mrna imaging by the target-triggered intracellular self-assembly
Electronic Supplementary Material (ESI) for Chemical Science. This journal is The Royal Society of Chemistry 2017 A smart ZnO@polydopamine-nucleic acid nanosystem for ultrasensitive live cell mrna imaging
More informationEvaluation of Markers for CpG Island Methylator Phenotype (CIMP) in Colorectal Cancer by a Large Population-Based Sample
JMD CME Program Journal of Molecular Diagnostics, Vol. 9, No. 3, July 2007 Copyright American Society for Investigative Pathology and the Association for Molecular Pathology DOI: 10.2353/jmoldx.2007.060170
More informationSupplementary Figure 1
Supplementary Figure 1 Supplementary Figure 1: Cryopreservation alters CD62L expression by CD4 T cells. Freshly isolated (left) or cryopreserved PBMCs (right) were stained with the mix of antibodies described
More informationIn ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours
Journal of Pathology Published online 21 January 2004 in Wiley InterScience (www.interscience.wiley.com). DOI: 10.1002/path.1521 Original Paper In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted
More informationCancer Genetics 204 (2011) 45e52
Cancer Genetics 204 (2011) 45e52 Exon scanning by reverse transcriptaseepolymerase chain reaction for detection of known and novel EML4eALK fusion variants in nonesmall cell lung cancer Heather R. Sanders
More informationAnatomic Molecular Pathology: An Emerging Field
Anatomic Molecular Pathology: An Emerging Field Antonia R. Sepulveda M.D., Ph.D. University of Pennsylvania asepu@mail.med.upenn.edu 2008 ASIP Annual Meeting Anatomic pathology (U.S.) is a medical specialty
More informationJournal of Cell Science Supplementary information. Arl8b +/- Arl8b -/- Inset B. electron density. genotype
J. Cell Sci. : doi:.4/jcs.59: Supplementary information E9. A Arl8b /- Arl8b -/- Arl8b Arl8b non-specific band Gapdh Tbp E7.5 HE Inset B D Control al am hf C E Arl8b -/- al am hf E8.5 F low middle high
More informationCross-talk between mineralocorticoid and angiotensin II signaling for cardiac
ONLINE SUPPLEMENT TO Crosstalk between mineralocorticoid and angiotensin II signaling for cardiac remodeling An Di ZHANG,,3, Aurelie NGUYEN DINH CAT*,,3, Christelle SOUKASEUM *,,3, Brigitte ESCOUBET, 4,
More informationSupplemental Information. Th17 Lymphocytes Induce Neuronal. Cell Death in a Human ipsc-based. Model of Parkinson's Disease
Cell Stem Cell, Volume 23 Supplemental Information Th17 Lymphocytes Induce Neuronal Cell Death in a Human ipsc-based Model of Parkinson's Disease Annika Sommer, Franz Maxreiter, Florian Krach, Tanja Fadler,
More informationSupplementary Figure 1
Supplementary Figure 1 Supplementary Figure 1. Lats1/2 deleted ihbs and ihps showed decreased transcripts of hepatocyte related genes (a and b) Western blots (a) and recombination PCR (b) of control and
More informationGuidelines for the assessment of mismatch repair (MMR) status in Colorectal Cancer
Guidelines for the assessment of mismatch repair (MMR) status in Colorectal Cancer Start date: May 2015 Review date: April 2018 1 Background Mismatch repair (MMR) deficiency is seen in approximately 15%
More informationSupplemental Information. Cancer-Associated Fibroblasts Neutralize. the Anti-tumor Effect of CSF1 Receptor Blockade
Cancer Cell, Volume 32 Supplemental Information Cancer-Associated Fibroblasts Neutralize the Anti-tumor Effect of CSF1 Receptor Blockade by Inducing PMN-MDSC Infiltration of Tumors Vinit Kumar, Laxminarasimha
More informationwww.lessonplansinc.com Topic: Protein Synthesis - Sentence Activity Summary: Students will simulate transcription and translation by building a sentence/polypeptide from words/amino acids. Goals & Objectives:
More informationCOLORECTAL PATHWAY GROUP, MANCHESTER CANCER. Guidelines for the assessment of mismatch. Colorectal Cancer
COLORECTAL PATHWAY GROUP, MANCHESTER CANCER Guidelines for the assessment of mismatch repair (MMR) status in Colorectal Cancer January 2015 1 Background Mismatch repair (MMR) deficiency is seen in approximately
More informationCOLORECTAL PATHWAY GROUP, MANCHESTER CANCER. Guidelines for the assessment of mismatch. Colorectal Cancer
COLORECTAL PATHWAY GROUP, MANCHESTER CANCER Guidelines for the assessment of mismatch repair (MMR) status in Colorectal Cancer March 2017 1 Background Mismatch repair (MMR) deficiency is seen in approximately
More informationDevelopment of Carcinoma Pathways
The Construction of Genetic Pathway to Colorectal Cancer Moriah Wright, MD Clinical Fellow in Colorectal Surgery Creighton University School of Medicine Management of Colon and Diseases February 23, 2019
More informationFormylpeptide receptor2 contributes to colon epithelial homeostasis, inflammation, and tumorigenesis
Supplementary Data Formylpeptide receptor2 contributes to colon epithelial homeostasis, inflammation, and tumorigenesis Keqiang Chen, Mingyong Liu, Ying Liu, Teizo Yoshimura, Wei Shen, Yingying Le, Scott
More informationBRAF mutation in colorectal carcinomas with signet ring cell component
Cancer Biol Med 2017. doi: 10.20892/j.issn.2095-3941.2017.0053 ORIGINAL ARTICLE BRAF mutation in colorectal carcinomas with signet ring cell component Serap Yalcin 1, Onder Onguru 2 1 Department of Molecular
More informationSerrated Polyps and a Classification of Colorectal Cancer
Serrated Polyps and a Classification of Colorectal Cancer Ian Chandler June 2011 Structure Serrated polyps and cancer Molecular biology The Jass classification The familiar but oversimplified Vogelsteingram
More informationice-cold 70% ethanol with gentle vortexing, incubated at -20 C for 4 hours, and washed with PBS.
Cell cycle analysis For cell cycle analysis, single cell suspensions of E12.5 fetal liver cells were suspended in 4 ml ice-cold 7% ethanol with gentle vortexing, incubated at -2 C for 4 hours, and washed
More informationBeta Thalassemia Sami Khuri Department of Computer Science San José State University Spring 2015
Bioinformatics in Medical Product Development SMPD 287 Three Beta Thalassemia Sami Khuri Department of Computer Science San José State University Hemoglobin Outline Anatomy of a gene Hemoglobinopathies
More informationBHP 2-7 and Nthy-ori 3-1 cells were grown in RPMI1640 medium (Hyclone) supplemented with 10% fetal bovine serum (Gibco), 2mM L-glutamine, and 100 U/mL
1 2 3 4 Materials and Methods Cell culture BHP 2-7 and Nthy-ori 3-1 cells were grown in RPMI1640 medium (Hyclone) 5 supplemented with 10% fetal bovine serum (Gibco), 2mM L-glutamine, and 100 U/mL 6 penicillin-streptomycin.
More informationBeta Thalassemia Case Study Introduction to Bioinformatics
Beta Thalassemia Case Study Sami Khuri Department of Computer Science San José State University San José, California, USA sami.khuri@sjsu.edu www.cs.sjsu.edu/faculty/khuri Outline v Hemoglobin v Alpha
More informationRESEARCH COMMUNICATION. Genotype Frequencies of Cyclooxygenease 2 (COX2) Rare Polymorphisms for Japanese with and without Colorectal Cancer
COX2 Rare Polymorphisms and Colorectal Cancer RESEARCH COMMUNICATION Genotype Frequencies of Cyclooxygenease 2 (COX2) Rare Polymorphisms for Japanese with and without Colorectal Cancer Nobuyuki Hamajima
More informationColorectal cancer Chapelle, J Clin Oncol, 2010
Colorectal cancer Chapelle, J Clin Oncol, 2010 Early-Stage Colorectal cancer: Microsatellite instability, multigene assay & emerging molecular strategy Asit Paul, MD, PhD 11/24/15 Mr. X: A 50 yo asymptomatic
More informationBeyond the APC era Alternative pathways to CRC. Jeremy R Jass McGill University
Beyond the APC era Alternative pathways to CRC Jeremy R Jass McGill University Outline Limitations of APC model KRAS and serrated polyps CRC and CpG island methylation Serrated pathway to CRC Fusion pathways
More informationA basic helix loop helix transcription factor controls cell growth
A basic helix loop helix transcription factor controls cell growth and size in root hairs Keke Yi 1,2, Benoît Menand 1,3, Elizabeth Bell 1, Liam Dolan 1,4 Supplementary note Low soil phosphate availability
More informationSUPPORTING INFORMATION
SUPPORTING INFORMATION Biology is different in small volumes: endogenous signals shape phenotype of primary hepatocytes cultured in microfluidic channels Amranul Haque, Pantea Gheibi, Yandong Gao, Elena
More informationClinicopathologic Characteristics of Left-Sided Colon Cancers with High Microsatellite Instability
The Korean Journal of Pathology 29; 43: 428-34 DOI: 1.4132/KoreanJPathol.29.43.5.428 Clinicopathologic Characteristics of Left-Sided Colon Cancers with High Microsatellite Instability Sang Kyum Kim Junjeong
More informationSupplementary Figure 1
Metastatic melanoma Primary melanoma Healthy human skin Supplementary Figure 1 CD22 IgG4 Supplementary Figure 1: Immunohisochemical analysis of CD22+ (left) and IgG4 (right), cells (shown in red and indicated
More informationColon Cancer and Hereditary Cancer Syndromes
Colon Cancer and Hereditary Cancer Syndromes Gisela Keller Institute of Pathology Technische Universität München gisela.keller@lrz.tum.de Colon Cancer and Hereditary Cancer Syndromes epidemiology models
More informationDescription of Supplementary Files. File Name: Supplementary Information Description: Supplementary Figures and Supplementary Tables
Description of Supplementary Files File Name: Supplementary Information Description: Supplementary Figures and Supplementary Tables Supplementary Figure 1: (A), HCT116 IDH1-WT and IDH1-R132H cells were
More informationIsolate Sexual Idiomorph Species
SUPLEMENTARY TABLE 1. Isolate identification, sexual idiomorph and species of each isolate used for MAT locus distribution in Paracoccidioides species. Isolate Sexual Idiomorph Species Pb01 MAT1-1 P. lutzii
More information*To whom correspondence should be addressed. This PDF file includes:
www.sciencemag.org/cgi/content/full/science.1212182/dc1 Supporting Online Material for Partial Retraction to Detection of an Infectious Retrovirus, XMRV, in Blood Cells of Patients with Chronic Fatigue
More informationwithout LOI phenotype by breeding female wild-type C57BL/6J and male H19 +/.
Sakatani et al. 1 Supporting Online Material Materials and methods Mice and genotyping: H19 mutant mice with C57BL/6J background carrying a deletion in the structural H19 gene (3 kb) and 10 kb of 5 flanking
More informationMolecular markers in colorectal cancer. Wolfram Jochum
Molecular markers in colorectal cancer Wolfram Jochum Biomarkers in cancer Patient characteristics Tumor tissue Normal cells Serum Body fluids Predisposition Diagnostic marker Specific diagnosis Prognostic
More informationA Review from the Genetic Counselor s Perspective
: A Review from the Genetic Counselor s Perspective Erin Sutcliffe, MS, CGC Certified Genetic Counselor Cancer Risk Evaluation Program INTRODUCTION Errors in base pair matching that occur during DNA replication,
More informationResistance to Tetracycline Antibiotics by Wangrong Yang, Ian F. Moore, Kalinka P. Koteva, Donald W. Hughes, David C. Bareich and Gerard D. Wright.
Supplementary Data for TetX is a Flavin-Dependent Monooxygenase Conferring Resistance to Tetracycline Antibiotics by Wangrong Yang, Ian F. Moore, Kalinka P. Koteva, Donald W. Hughes, David C. Bareich and
More informationDepartment of Pathology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
& 2008 USCAP, Inc All rights reserved 0893-3952/08 $30.00 www.modernpathology.org CpG island methylator phenotype-low (CIMP-low) colorectal cancer shows not only few methylated CIMP-high-specific CpG islands,
More informationSupporting Information
Supporting Information Guney et al. 1.173/pnas.117218 SI Materials and Methods PCR and Genotyping. Genotyping of CTGF e2coin/e2coin mice was performed by PCR on N isolated from ear punches using the following
More informationSupplementary information
Supplementary information Unique polypharmacology nuclear receptor modulator blocks inflammatory signaling pathways Mi Ra Chang 1, Anthony Ciesla 1, Timothy S. Strutzenberg 1, Scott J. Novick 1, Yuanjun
More informationCurrent Status of Biomarkers (including DNA Tumor Markers and Immunohistochemistry in the Laboratory Diagnosis of Tumors)
Current Status of Biomarkers (including DNA Tumor Markers and Immunohistochemistry in the Laboratory Diagnosis of Tumors) Kael Mikesell, DO McKay-Dee Hospital May 14, 2015 Outline Update to DNA Testing
More informationInt J Clin Exp Pathol 2013;6(6): /ISSN: /IJCEP Tadashi Terada
Int J Clin Exp Pathol 2013;6(6):1150-1156 www.ijcep.com /ISSN:1936-2625/IJCEP1303005 Case Report Urinary bladder urothelial carcinoma with expression of KIT and PDGFRA and showing diverse differentiations
More informationObjectives. Briefly summarize the current state of colorectal cancer
Disclaimer I do not have any financial conflicts to disclose. I will not be promoting any service or product. This presentation is not meant to offer medical advice and is not intended to establish a standard
More informationEvolution of Pathology
1 Traditional pathology Molecular pathology 2 Evolution of Pathology Gross Pathology Cellular Pathology Morphologic Pathology Molecular/Predictive Pathology Antonio Benivieni (1443-1502): First autopsy
More informationNucleotide Sequence of the Australian Bluetongue Virus Serotype 1 RNA Segment 10
J. gen. Virol. (1988), 69, 945-949. Printed in Great Britain 945 Key words: BTV/genome segment lo/nucleotide sequence Nucleotide Sequence of the Australian Bluetongue Virus Serotype 1 RNA Segment 10 By
More informationDevelopment of RT-qPCR-based molecular diagnostic assays for therapeutic target selection of breast cancer patients
Development of RT-qPCR-based molecular diagnostic assays for therapeutic target selection of breast cancer patients Sangjung Park The Graduate School Yonsei University Department of Biomedical Laboratory
More informationRamya Thota 1, Xiang Fang 2, Shanmuga Subbiah 3. Introduction
Original Article Clinicopathological features and survival outcomes of primary signet ring cell and mucinous adenocarcinoma of colon: retrospective analysis of VACCR database Ramya Thota 1, Xiang Fang
More informationHigh overexpression of fatty acid synthase is associated with poor survival in Chinese patients with gastric carcinoma
EXPERIMENTAL AND THERAPEUTIC MEDICINE 4: 999-1004, 2012 High overexpression of fatty acid synthase is associated with poor survival in Chinese patients with gastric carcinoma WENMIN HOU 1,2*, MAOGUI FEI
More informationRelationship of the APOA5/A4/C3/A1 gene cluster and APOB gene polymorphisms with dyslipidemia
elationship of the APOA5/A4/C3/A1 gene cluster and APOB gene polymorphisms with dyslipidemia H.J. Ou 1, G. Huang 2, W. Liu 3, X.L. Ma 2, Y. Wei 4, T. Zhou 5 and Z.M. Pan 3 1 Department of Neurology, The
More informationSupplementary Information. Bamboo shoot fiber prevents obesity in mice by. modulating the gut microbiota
Supplementary Information Bamboo shoot fiber prevents obesity in mice by modulating the gut microbiota Xiufen Li 1,2, Juan Guo 1, Kailong Ji 1,2, and Ping Zhang 1,* 1 Key Laboratory of Tropical Plant Resources
More informationBaseline clinical characteristics for the 81 CMML patients Routine diagnostic testing and statistical analyses... 3
Next-Generation Sequencing Technology Reveals a Characteristic Pattern of Molecular Mutations in 72.8% of Chronic Myelomonocytic Leukemia (CMML) by Detecting Frequent Alterations in TET2, CBL, RAS, and
More informationThe Clinical Performance of Primary HPV Screening, Primary HPV Screening Plus Cytology Cotesting, and Cytology Alone at a Tertiary Care Hospital
The Clinical Performance of Primary HPV Screening, Primary HPV Screening Plus Cytology Cotesting, and Cytology Alone at a Tertiary Care Hospital Jung-Woo Choi MD, PhD; Younghye Kim MD, PhD; Ju-Han Lee
More informationDefective mismatch repair in the pathogenesis of low-grade appendiceal mucinous neoplasms and adenocarcinomas
& 2004 USCAP, Inc All rights reserved 0893-3952/04 $30.00 www.modernpathology.org Defective mismatch repair in the pathogenesis of low-grade appendiceal mucinous neoplasms and adenocarcinomas Joseph Misdraji
More informationLezione 10. Sommario. Bioinformatica. Lezione 10: Sintesi proteica Synthesis of proteins Central dogma: DNA makes RNA makes proteins Genetic code
Lezione 10 Bioinformatica Mauro Ceccanti e Alberto Paoluzzi Lezione 10: Sintesi proteica Synthesis of proteins Dip. Informatica e Automazione Università Roma Tre Dip. Medicina Clinica Università La Sapienza
More informationPATIENTS AND METHODS. Subjects
PATIENTS AND METHODS Subjects Twenty-nine morbidly obese subjects involved in a gastric surgery program were enrolled in the study between October 25 and March 21. Bariatric surgery was performed in patients
More informationExpression of Selected Inflammatory Cytokine Genes in Bladder Biopsies
Borneo Journal of Resource Science and Technology (2013) 3(2): 15-20 Expression of Selected Inflammatory Cytokine Genes in Bladder Biopsies EDMUND UI-HANG SIM *1, NUR DIANA ANUAR 2, TENG-AIK ONG 3, GUAN-
More informationSupplementary Information
Supplementary Information Remodeling of heterochromatin structure slows neuropathological progression and prolongs survival in an animal model of Huntington s disease Junghee Lee, Yu Jin Hwang, Yunha Kim,
More informationHereditary non-polyposis colorectal cancer is predicted to contribute towards colorectal cancer in young South African blacks
68 South African Journal of Science 105, January/February 2009 Research Articles Hereditary non-polyposis colorectal cancer is predicted to contribute towards colorectal cancer in young South African blacks
More informationLynch Syndrome Screening for Endometrial Cancer: Basic Concepts 1/16/2017
1 Hi, my name is Sarah Kerr. I m a pathologist at Mayo Clinic, where I participate in our high volume Lynch syndrome tumor testing practice. Today I hope to cover some of the basics needed to understand
More informationGeneral Session 7: Controversies in Screening and Surveillance in Colorectal Cancer
General Session 7: Controversies in Screening and Surveillance in Colorectal Cancer Complexities of Pathological Assessment: Serrated Polyps/Adenomas Carolyn Compton, MD, PhD Professor of Life Sciences,
More informationColorectal Cancer Expression of Peroxisome Proliferator-Activated Receptor (PPARG, PPARgamma) Is Associated With Good Prognosis
GASTROENTEROLOGY 2009;136:1242 1250 Colorectal Cancer Expression of Peroxisome Proliferator-Activated Receptor (PPARG, PPARgamma) Is Associated With Good Prognosis SHUJI OGINO,*,, KAORI SHIMA,* YOSHIFUMI
More informationSupporting Information
Supporting Information Malapeira et al. 10.1073/pnas.1217022110 SI Materials and Methods Plant Material and Growth Conditions. A. thaliana seedlings were stratified at 4 C in the dark for 3 d on Murashige
More informationMcAlpine PERK-GSK3 regulates foam cell formation. Supplemental Material. Supplementary Table I. Sequences of real time PCR primers.
Mclpine PERK-GSK3 regulates foam cell formation Supplemental Material Supplementary Table I. Sequences of real time PCR primers. Primer Name Primer Sequences (5-3 ) Product Size (bp) GRP78 (human) Fwd:
More information